

# Presidents



**Claudio Cerchione**  
Istituto  
Scientifico Romagnolo  
per lo Studio e la Cura  
dei Tumori (IRST) IRCCS  
Italy



**David W. Greening**  
Baker Heart and  
Diabetes Institute  
La Trobe University  
Australia



**Antonia Reale**  
Monash University  
The Alfred  
Australia



**Andrew Spencer**  
Monash University  
The Alfred  
Australia



**Angelo Vacca**  
University  
of Bari Aldo Moro  
Italy

## Scientific Board

C. Cerchione D. W. Greening  
G. Martinelli A. Reale  
R. Ria A. Spencer A. Vacca

## Scientific Secretariat

C. Cerchione D. W. Greening  
A. Frassanito A. Melaccio  
A. Reale G. Simonetti  
A.G. Solimando A. Spencer A. Vacca



**1 JULY 2021**

**preliminary program**

# SOHO ITALY EXTRACELLULAR VESICLES AND THEIR ROLE IN PATIENTS WITH MULTIPLE MYELOMA




**webinar**

**FREE  
REGISTRATION**

**[www.sohoitaly.it](http://www.sohoitaly.it)**



**ORGANIZING SECRETARIAT**



**[info@proeventi.it](mailto:info@proeventi.it)  
[www.proeventi.it](http://www.proeventi.it)**



# EXTRACELLULAR VESICLES AND THEIR ROLE IN PATIENTS WITH MULTIPLE MYELOMA

1 JULY 2021

In the past decade, there have been major advances in the treatment of the blood cancer Multiple Myeloma (MM). The introduction of novel agents such as immune-modifying agents (IMiDs), proteasome inhibitors, monoclonal antibodies, with or without stem cell transplantation, has resulted in significantly improved patient survival. Meanwhile, the increased understanding of MM tumor biology has provided a rationale for new combinations of drugs and risk-adapted and individualized treatments to further improve patient management.

Extracellular vesicles (EVs) are cell-derived membranous particles that mediate cell-to-cell communication by transferring proteins, lipids and nucleic acids locally and through systemic circulation. EVs are active regulators in the cross-talk between MM tumour cells and bone marrow microenvironment, with the capacity to alter angiogenesis, osteoclast differentiation and immunosuppression, promoting tumour progression and drug resistance. Circulating EVs containing tumour-specific molecular signatures (oncoproteins, RNAs, DNA fragments) have potential clinical utility as next-generation liquid biopsy biomarkers in cancer diagnosis and management, with the potential to characterise both spatial heterogeneity and clonal evolution thus informing new modalities for diagnosis, risk stratification, monitoring and therapeutic intervention in MM. However, the nano-scale nature of EVs and the complexity of biofluids present challenges that need to be addressed before the potential of EVs as biomarkers and therapeutic targets can be achieved.

The Italian Society of Hematologic Oncology (SOHO Italy) was established as a non-profit organization in 2019 to promote worldwide research (education, prevention, preclinical and clinical studies and patient care) of hematologic malignancies and related disorders. In this scenario, SOHO Italy together with Australian colleagues aim to bring together international experts to discuss the latest advances in the pathophysiology and therapy of MM and to better understand the role of EVs in patients with MM.



# EXTRACELLULAR VESICLES AND THEIR ROLE IN PATIENTS WITH MULTIPLE MYELOMA

1 JULY 2021

Italian time 🕒

## 07.50 OPENING REMARKS

C. Cerchione D. W. Greening A. Reale A. Spencer A. Vacca

## SESSION 1

### THE MULTIPLE MYELOMAS

Chair E. Hermann A. Spencer G. Martinelli

08.00 Soho USA & Soho Italy TBC

08.20 The Multiple Myelomas - biology, diagnosis, risk stratification TBC

08.40 Role of microenvironment in MM A. Vacca

09.00 Immune system in MM P. Neri

09.20 Abstract submission

09.30 **Lecture** Liquid biopsy in MM A. Spencer

BREAK

## SESSION 2

### UNDERSTANDING EXTRACELLULAR VESICLES

Chair D. W. Greening A. Vacca C. Blenkiron

10.20 Extracellular vesicles - overview, update K. Witwer

10.40 Extracellular vesicles in cancer—implications for future improvements in cancer care A. Rai

11.00 EV bystander signaling and cancer resistance P. Samuel

11.20 Extracellular vesicles as cancer diagnostics A. Möller

11.40 Tools for tracking biodistribution of cancer EVs C. Lai

12.00 Abstract submission

12.10 Student/ECR Network on EVs (SNEV), overview A. Nasiri Kenari

LUNCH

## SESSION 3

### HOW I MANAGE MULTIPLE MYELOMA

Chair K.C. Anderson M.V. Mateos C. Cerchione

12.55 How I manage frontline MM M. V. Mateos

13.15 How I manage relapsed/refractory MM C. Cerchione

13.35 Biologically Based Therapies for MM K.C. Anderson

13.55 New treatment avenues in MM H.C. Lee

14.15 Managing infections in MM R. Ria

14.35 Abstract submission

BREAK

## SESSION 4

### ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

Chair C. Lai G. Simonetti A. Reale

14.55 EVs in MM progression A. Roccaro

15.15 EVs in MM bone disease K. Vanderkerken

15.35 miRNA- charged vesicles and drug resistance in MM T. Umez

15.55 MM-small EVs, omics, plasma A. Reale

16.15 Large EVs as liquid biomarkers in MM A. Caivano

16.35 Abstract submission

16.45 **Lecture** Proteomic insights in EVs: key players in cancer and potential therapeutic strategy D. W. Greening

17.15 **CONCLUDING REMARKS**

C. Cerchione G. Martinelli A. Vacca